Suppression of plasma viral load below 20 copies/ml is required to achieve a long-term response to therapy

AIDS

Volumn 12, Issue 13, 1998, Pages 1619-1624

  Raboud, Janet M ^a   Montaner, Julio S G ^a   Conway, Brian ^a   Rae, Sandra ^a   Reiss, Peter ^b   Vella, Stephano ^c   Cooper, David ^d   Lange, Joep ^b   Harris, Marianne ^a   Wainberg, Mark A ^e   Robinson, Patrick ^f   Myers, Maureen ^f   Hall, David ^f  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

^c ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^d ST VINCENT S HOSPITAL   (Australia)

^e MCGILL UNIVERSITY   (Canada)

^f BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

Author keywords

Antiretroviral therapy; HIV RNA; Suppression; Viral load

Indexed keywords

CD4 ANTIGEN; DIDANOSINE; NEVIRAPINE; ZIDOVUDINE;

ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK; T LYMPHOCYTE; TREATMENT FAILURE; TREATMENT OUTCOME; VIRUS LOAD;

ANTI-HIV AGENTS; AUSTRALIA; CANADA; CD4 LYMPHOCYTE COUNT; DIDANOSINE; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; HIV INFECTIONS; HIV-1; HUMANS; ITALY; NETHERLANDS; NEVIRAPINE; REVERSE TRANSCRIPTASE INHIBITORS; RNA, VIRAL; VIRAL LOAD; ZIDOVUDINE;

EID: 7344250684     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-199813000-00008     Document Type: Article

References (13)

1. Carpenter CCJ, Fischl MA, Hammer SM, et al.: Consensus statement: antiretroviral therapy for HIV infection in 1996. Recommendations of an international panel. JAMA 1996, 276:146-154.
2. BHIUA Guidelines Co-ordinating Committee: British HIV Association guidelines for antiretroviral treatment of HIV seropositive individuals. Lancet, 1997, 349:1086-1092.
3. 3. Jama 1998, 279:930-937.
4. Mulder J, McKinney N, Christopherson C, Sninsky J, Greenfield L, Kwok S: Rapid and simple PCR assay for quantitation of human immunodeficiency virus type 1 RNA in plasma: application to acute retroviral infection. J Clin Microbiol 1994, 32:292-300.
5. Mulder J, Resnick R, Sagel B, et al.: A rapid and simple method for extracting human immunodeficiency virus type 1 RNA from plasma: enhanced sensitivity. J Clin Microbiol 1997, 35:1278-1280.
6. Vella S, Floridia M, Tomino C, et al.: Zidovudine plus didanosine plus nevirapine vs zidovudine plus didanosine in antiretroviral naive patients with very advanced disease International Workshop on HIV Drug Resistance, Treatment Strategies and Eradication. St Petersburg, June 1997 [abstract 57].
7. Ceasar Coordinating Committee: Randomised trial of addition of lamivudine or lamivudine plus loviride to zidovudine-containing regimens for patients with HIV-1 infection: the CAESAR trial. Lancet 1997, 349:1413-1421.
8. Montaner JSG, DeMasi R, Hill AM: The effects of lamivudine treatment on HIV-1 disease progression are highly correlated with plasma HIV-1 RNA and CD4 cell count. AIDS 1998, 12:123-128.
9. OBrien WA, Hartigan PM, Daar ES, Simberkoif MS, Hamilton JD: Changes in plasma HIV RNA levels and CD4+ lymphocyte counts predict both response to antiretroviral therapy and therapeutic failure. VA Cooperative Study Group on AIDS. Ann Intern Med 1997, 126:939-945.
10. Goebel F: AVANTI 2. A randomized, double blind, comparative trial to evaluate combination antiretroviral regimens for the treatment of HIV-1 infection: AZT/3TC/indinavir in antiretroviral naive patients. Sixth European Conference on Clinical Aspects and Treatment of HIV-Infection. Hamburg, October 1997 [abstract 211].
11. Clumeck N: AVANTI 3. A randomized, double blind, comparative trial to evaluate the efficacy, safety and tolerance of AZT/3TC vs AZT/3TC/nelfinavir in antiretroviral naive patients. Fifth Conference on Retroviruses and Opportunistic Infections. Chicago, February 1998 [abstract 8].
12. Kahn J, Mayers D, Riddler S, et al.: Durable clinical anti-HIV-1 activity (60 Weeks) and tolerability for efavirenz (DMP 266) in combination with indinavir (IDV): suppression to '<1 copy/ml' (OD = background) by Amplicor as a predictor of virologic treatment response (DMP 266-003, Cohort IV). Fifth Conference on Retroviruses and Opportunistic Infections. Chicago, February 1998 [abstract 692].
13. Kempf D, Molla A, Sun E, et al.: The duration of viral suppression is predicted by viral load during protease inhibitor therapy. Fourth Conference on Retroviruses and Opportunistic Infections, Washington, DC, January 1997 [abstract 603].